Companies › Nova Therapeutics
1 active drug program in 1 registered trial: 1 Phase 1; Oncology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CART-PSMA cells CAR-T cell therapy targeting PSMA (prostate-specific membrane antigen) | PSMA | Phase 1 | Prostate Cancer | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05656573 | CART-PSMA cells | Phase 1 | Prostate Cancer | Oncology | Dec 2025 |
Cash and short-term investments of $536m on 2025-12-31; operating cash flow positive
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.